About BrainStorm

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Learn More

Latest News

All News

NurOwn® Clinical Development Program Webinar Hosted by NEALS

On July 17th, the Northeast ALS Consortium (NEALS) hosted a research webinar on the NurOwn® Clinical Development Program: Promising Phase 2 Results, Phase 3 Study Overview, and Hospital Exemption Program Update. They were joined by Robert Brown, MD, DPhil, University of Massachusetts, Merit Cudkowicz, MD, MSc, Massachusetts General Hospital, Anthony Windebank, MD, Mayo Clinic, Ralph Kern, MD, MHSc, BrainStorm Cell Therapeutics and Chaim Lebovits, BrainStorm Cell Therapeutics.



Learn More